

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

For the Japanese version, please refer to the Japanese PR of "Notice of Publication of Transcript of logmi Finance. Financial Results Briefing for the Fiscal Year Ending June 2025" published on August 22, 2025.

Financial Results Report

FY 06/2025

OLBA HEALTHCARE HOLDINGS, INC.
(formerly KAWANISHI HOLDINGS INC.)

This presentation includes machine translation.
Please consider that some content may not be perfectly accurate or contextually appropriate.

(Securities code: 2689)



[Title]

OLBA HEALTHCARE HD achieves record-high net sales for the fifth consecutive year; driving market expansion through the establishment of Kansai Branch

[Lead]

The following is a transcript of the financial results presentation of OLBA HEALTHCARE HOLDINGS, Inc. for the fiscal year ended June 30, 2025, which was announced on August 22, 2025.

[Speaker]

Yohei Maeshima, President and CEO, OLBA HEALTHCARE HOLDINGS, Inc.

Contents

Contents

- ◆ Corporate Philosophy
- ◆ Summary of FY 06/2025
- ◆ FY2026 Forecast of Results and Basic Policy for Distribution
- ◆ Outline of the Medium-Term Management Plan
- ◆ Reference Materials

Maeshima: I am Yohei Maeshima, President and CEO of OLBA HEALTHCARE HOLDINGS, Inc. Thank you for taking time out of your busy schedule today to join our group's financial results presentation. I will proceed in line with the slides.

Corporate Philosophy and Significance of Presence (purpose)

**Aiming to develop medical science,
medical care, and long-term nursing
care through our business endeavors**



社員憲章

事業のあり方

- ビジネスを通じて、医学・医療・介護の発展に貢献し、国民の健康長寿に寄与する
- 革新的な新機軸・新技術の意思を、患者と医療機関に速やかに適切に提供する
- ステークホルダー（顧客、取引先、社員、地域社会、株主）の聲援に、誠実かつ積極的に感謝を表明し、持続可能な成長を追求する
- 業界の内外を問わず積極的に関わり、創造性を育み、グローバルな視点でプロンティアを開拓する

組織のあり方

- 人材育成を重視し、「マネジメント（人を通じて事を成す）」に重きを置く

4

COLBA HEALTHCARE HOLDINGS, Inc.

First, I will explain our corporate philosophy. Our corporate philosophy, or purpose, is contributing to the development of medicine, healthcare, and nursing care through our business, thereby supporting the health and longevity of society.”

Under this corporate philosophy, we share the missions of “contributing as a part of the regional medical infrastructure” and “ensuring the continuity of medical and nursing care” among all employees, and carry out our activities on a daily basis.


Japan's Domestic Medical Equipment Market Size

Domestic market size of medical devices

Stable market growth despite policies to curb medical costs

- Recovering from the Impact of the New Corona and Stable Market Expansion
- Market expansion due to increase in number of surgeries and introduction of new products

In fiscal 2024,
Forecast of ¥3.794 trillion



* Processed from the 2023 edition of the Medical Equipment and Supply Yearbook and the 2024 edition of the Medical Equipment and Supply Yearbook of R&D Co., Ltd.

©OLBA HEALTHCARE HOLDINGS, Inc.

6

I will now provide an overview of our financial results for the fiscal year ended June 30, 2025. Before discussing our financial results, I would like to touch on the domestic market environment.

The domestic medical equipment market has been growing steadily despite the government's cost-containment policies in healthcare. Furthermore, it has recovered from the impact of COVID-19, and driven by an increase in the number of surgeries and the introduction of new products, the market is projected to reach JPY3.794 trillion in fiscal 2024.

Performance Topics: Market Environment

■ Global inflation and depreciation of the yen

- Prices of medical devices, many of which are overseas products, continue to trend upward
 - ⇒ Implemented measures to expand sales activities and improve purchasing
 - ⇒ Conducted negotiations to pass on the increase to sales prices while considering proposals for alternative products

■ Refrained capital investment at medical institutions

- Decrease in subsidies such as supplementary budget
- Deterioration in the business environment at some medical institutions due to increases in labor costs and resource prices
 - ⇒ Expand sales to non-medical institutions through new businesses

■ Consolidation of advanced medical functions

- Consolidation of advanced and specialized medical in certain large hospitals
- Consolidate doctors, nurses, and medical facilities to maintain a high-quality healthcare delivery system.
 - ⇒ Company main customers are regional core hospitals. For medical institutions by strengthening cooperation with medical device manufacturers Support

7

COLBA HEALTHCARE HOLDINGS, Inc.

I would like to share with you the current environment surrounding us and our response to it. First, as a result of global inflation and the weak yen, prices for medical equipment, many of which are made overseas, continue to rise. We are working to expand sales activities and improve procurement, while also proposing alternative products tailored to the needs of medical institutions and negotiating the pass-through of costs to selling prices.

In addition, we have observed a tendency among medical institutions to restrain capital investment. This is largely attributable to the reduction of subsidies for COVID-19 measures and the increase in labor and resource costs, which have placed pressure on the business environment of certain institutions. To address this, we are expanding our sales channels beyond medical institutions through new business initiatives.

Furthermore, the trend toward the consolidation of advanced medical functions is accelerating. The government aims to maintain a high-quality healthcare delivery system by concentrating advanced and specialized medical services in certain large-scale hospitals.

Our primary customers are core regional hospitals, and we will continue to strengthen our partnerships with medical equipment manufacturers while providing ongoing support to medical institutions.

Performance Topics: Our Status

■ Establishment of Kansai Branch in mainstay medical equipment business

- Acquired customers in the Kansai area and promoted Kobe Sales Office to Kansai Branch
⇒ Sales of the area's mainstay orthopedic consumables increased 10.6% year on year in total.

■ Strong sales of consumables

- Increase in consumables sales due to an increase in the number of procedures performed
⇒ Both surgical consumables and cardiovascular consumables increased YoY.

■ Sluggish sales of equipment

- Refrain from capital investment due to deterioration in the business environment of medical institutions
⇒ Sales decreased more than initially expected due to postponement of equipment upgrades, etc.
⇒ Despite sales of automatic settlement machines and low-thermal decomposition-type up-cycle units, budget has not been achieved.

Let me now highlight the key topics of our Group's performance for the fiscal year ended June 30, 2025. In our core Medical Devices and Consumables Business, we established the Kansai Branch. As we continued to acquire customers in the Kansai area, we upgraded the Kobe Sales Office to the Kansai Branch in 2024. As a result, sales of consumables in the orthopedic field, which is our mainstay in this region, increased significantly by 10.6% year on year.

Along with an increase in the number of surgeries, sales of surgery-related and cardiovascular-related consumables also increased year on year.

On the other hand, sales of fixtures remained sluggish due to the deteriorating business environment of medical institutions. Sales fell significantly below initial forecasts due to factors such as the postponement of equipment upgrades. We also focused on sales of automated payment machines and low-temperature decomposition upcycling units to non-hospital customers, but failed to achieve our budget targets.

Consolidated Financial Results for the Fiscal Year Ended June 30, 2025

Consolidated Financial Results for the Fiscal Year Ended June 2025

Net sales reached a record high, but profits declined

	Millions of yen	Comparison with budget	YoY change
Net sales	122,702	Δ0.8%	+3.5%
Gross profit	13,909	Δ3.7%	+2.3%
Gross profit margin	11.34%	Δ0.34	Δ0.14
SG&A expenses	11,929	Δ2.0%	+4.9%
Operating income	1,979	Δ12.8%	Δ11.1%
Ordinary income	1,962	Δ12.9%	Δ12.6%
Profit attributable to owners of parent	1,430	Δ14.9%	Δ4.7%

Net income per share ¥241.43

9


© COLBA HEALTHCARE HOLDINGS, Inc.

For the consolidated results of the fiscal year ending June 2025, net sales were JPY122,702 million, operating profit was JPY1,979 million, ordinary profit was JPY1,962 million, and profit attributable to owners of parent was JPY 1,430 million. While net sales reached a record high, profits declined.

Basic earnings per share was JPY241.43.

Factors behind Changes in Operating Profit for the Fiscal Year Ended June 30, 2025

Factors behind Changes in Operating Income for the Fiscal Year Ended June 2025



Regarding the factors behind the change in operating profit for the fiscal year ended June 30, 2025 compared with the fiscal year ended June 30, 2024: while sales of consumables in the Medical Devices and Consumables business continued to grow steadily, sales of equipment and fixtures declined significantly.

In addition, across all businesses, we implemented a base salary increase in anticipation of future growth, and made substantial investments in human capital, such as employee training, as well as proactive system investments, resulting in a significant increase in selling, general and administrative expenses (SG&A).


As a result, operating profit decreased by JPY248 million year on year to JPY1,979 million.

Results for the Fiscal Year Ended June 30, 2025 by Business Segment

Results by Business Segment for the Fiscal Year Ended June 2025

Sales Mix

■ Medical equipment ■ SPD ■ Nursing care products



[FY2025] Net sales (operating profit)

※Sales include inter-segment sales

115.8 billion yen
(1.77 billion yen)



Medical equipment business
Total partners in the medical field

5.7 billion yen
(110 million yen)



SPD business
Medical products distribution specialist

2.7 billion yen
(200 million yen)



Nursing Care Products Business
Total support for nursing care products

11

©OLBA HEALTHCARE HOLDINGS, Inc.

I will present net sales and operating profit by business segment. In terms of sales composition, our core Medical Devices and Consumables business accounted for 93.2%, followed by the SPD business at 4.6% and the Nursing Care Products business at 2.2%.

I will explain details of the Medical Devices and Consumables business in the following slides.

Medical Devices and Consumables

Medical equipment business




Total partners in the medical field

Millions of yen	Actual	Comparison with budget	YoY change
Net sales ^{※1}	115,878	Δ0.9%	+3.3%
Operating income	1,774	Δ13.7%	Δ12.9%



Medical equipment [93.2%]



Millions of yen	Sales Results ^{※2}	YoY change
Kawanishi Corporation	77,114	+2.9%
Sansei Medical	27,501	+1.4%
Nikko Medical Instruments	12,250	+8.5%

※1 Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

※2 Sales results of individual companies include the amount of transactions between group companies

12

©OLBA HEALTHCARE HOLDINGS, Inc.

Net sales for the Medical Devices and Consumables business were JPY115,878 million, up 3.3% year on year. Operating profit was JPY1,774 million, down 12.9% year on year.

At the bottom right of the slide, you can see the net sales results and year-on-year changes for each operating company. While sales of consumables grew steadily, fixtures sales were weak, leading to higher net sales but lower operating profit.

Medical Devices and Consumables: Consumables

Medical Equipment Business Consumables

Sales ¥103.4 billion up 6.5% year on year

Millions of yen

Product Classification	Net sales	YoY change	Points of sub-segments
Surgical consumables	50,457	+3.9%	Increase in number of surgical procedures and steady progress in Olympus distributor activities Medical (including diabetes) +12.3%, Surgery +5.2% Digestive endoscopes +5.1%
Orthopedic consumables	28,885	+10.6%	Strong sales of consumables related to sales of robotics and navigation systems Artificial joint +10.5%, trauma, sports, arthroscopes +8.3%, spine +1.2%
Cardiovascular consumables	24,083	+7.2%	Development of new customers and strong sales of new products related to arrhythmia treatment Catheterization ABL*+13.4%, cardiac ischemic treatment + 8.8%. Cardiac and Vascular Surgery Δ 3.1%

* ABL: Therapy in which a portion of the heart is catheterized for a tachyarrhythmia, such as auricular fibrillation, to be ablated or frozen



Ultrasound scalpel

Johnson & Johnson K.K.
From our website (<https://www.jnj.co.jp/>)



Artificial knee joint

Zimmer Biomet website
From <https://www.zimmerbiomet.com/jp/>



Pacemaker

Medtronic website
From <https://www.medtronic.com/>

※ Net sales (including changes from the previous fiscal year) are calculated based on management accounting before the adoption of the new revenue recognition standard.

13

Net sales of consumables in the Medical Devices and Consumables were JPY103.4 billion, an increase of 6.5% year on year. I will explain the breakdown in three product categories.

Sales of surgery-related consumables increased by 3.9% year on year, due to an increase in the number of surgeries and our successful activities as an agent for Olympus Marketing Inc.

As for orthopedic consumables, the widespread adoption of robotic surgery has driven robust sales of consumables related to sales of robotic navigation system, resulting in a 10.6% increase in overall net sales.

In cardiovascular consumables, overall sales increased by 7.2%, driven by the acquisition of new customers and strong sales of new products related to arrhythmia treatment. All product categories recorded year-on-year growth.

Medical Devices and Consumables: Equipment and Fixtures

Medical Equipment Business Equipment

Net sales ¥14.6 billion YoY 14.5% down

Points of Equipment Sales

- ◆Increase in demand due to subsidies for new corona, etc. paused
- ◆Decline in willingness to invest in facilities due to deterioration in the business environment of hospitals
- ◆Sales of automated payment machines for clinics were strong.



Automatic reset machine
From kawamishibankmed HP
(<https://kawamishi-bm.co.jp/>)



Pulmotor

Philips website
Than <https://www.philips.co.jp/healthcare>



With analysis function
Vital signs monitor

Fukuda Electronic Website
From (<https://www.fukuda.co.jp/>)

14

©OLBA HEALTHCARE HOLDINGS, Inc.

Net sales of equipment and fixtures in the Medical Devices and Consumables business were JPY14.6 billion, a decrease of 14.5% year on year.

The decrease in subsidies related to COVID-19 and the rise in personnel expenses worsened the management environment for hospitals, leading to a trend of restrained capital investment. On the other hand, sales of automated payment machines for clinics remained strong.

Medical products distribution specialist

Millions of yen	Actual	Comparison with budget	YoY change
Net sales ※	5,717	+4.0%	+9.4%
Operating income	113	+4.2%	+9.0%
Total number of subscribers	※Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales		
74 direct			
FC 2			

- ◆ Review of commodity management service fees
- ◆ Passing on increases in purchase prices to higher prices and making improvements in purchases
- ◆ Increase in SG&A expenses due to the impact of salary base pay increases, etc.



Goods management



Information management



Purchasing management



15

©OLBA HEALTHCARE HOLDINGS, Inc.

This slide is about the SPD business. Due to factors such as revised fees for goods management services at contracted medical facilities that already use our services, net sales were JPY5,717 million, up 9.4% year on year.

Operating profit was JPY113 million, up 9.0% year on year. This was due to our efforts to secure profits by passing on the increased costs to selling prices and by improving procurements, which were partially offset by an increase in SG&A expenses due to factors such as rise in the base salary.

Nursing Care Products Business

Nursing Care Products Business



Total support for nursing care products

Millions of yen	Actual	Comparison with budget	YoY change
Net sales ※	2,777	+0.2%	+5.2%
Operating income	205	Δ11.5%	Δ1.8%

※ Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

- ◆ Continued demand for home medical care and in-home nursing care
- ◆ Mainstay nursing care product rentals up 4.7% YoY
- ◆ Merchandise sales associated with rentals up 10.8% YoY
- ◆ Housing renovations also performing well
- ◆ Operating income decreased YoY due to expenses associated with the opening of Kochi stores.



Rental



Sales



Renovation



16

© OLBA HEALTHCARE HOLDINGS, Inc.

Next is the Nursing Care Products business. Demand for home medical care and in-home nursing care continued to be high, and sales of our mainstay nursing care products rentals increased steadily by 4.7% year on year.

Sales of merchandise and the home renovation were also strong. As a result, net sales were JPY2,777 million, up 5.2% year on year. On the other hand, operating profit was JPY205 million, down 1.8% year on year.

The main factors behind the decrease in operating profit are upfront investments for future business expansion, such as expenses associated with opening a new store in Kochi.

Consolidated Financial Forecast for the Fiscal Year Ending June 30, 2026

Forecast of Consolidated Financial Results for the Fiscal Year Ending June 2026

Net sales and gross profit are expected to reach record highs and operating income is expected to increase slightly

(Millions of yen)	Forecast	2025/6 Result	Change
Net sales	127,978	122,702	+4.3%
Gross profit	14,856	13,909	+6.8%
Gross profit margin	11.61%	11.34%	+0.27
SG&A expenses	12,856	11,929	+7.8%
Operating income	2,000	1,979	+1.0%
Ordinary income	1,928	1,962	△1.7%
Profit attributable to owners of parent	1,321	1,430	△7.6%

Net income per share ¥223.04

18

© COLBA HEALTHCARE HOLDINGS, Inc.

I will explain our earnings forecast and basic dividend policy for the fiscal year ending June 30, 2026. I will begin with our full-year consolidated earnings forecast for the fiscal year ending June 30, 2026.


We forecast net sales of JPY127,978 million, operating profit of JPY2,000 million, ordinary profit of JPY1,928 million, and profit attributable to owners of parent of JPY1,321 million.

We expect to achieve record-high net sales and gross profit. The decrease in profit attributable to owners of parent was due to the absence of one-time accounting effects recorded in previous fiscal year in connection with a subsidiary's head office relocation and integration plan.

I will explain the main factors behind the increase in operating profit on the next slide.

Factors behind Changes in Operating Profit for the Fiscal Year Ending June 30, 2026

Factors behind Changes in Operating Income for the Fiscal Year Ended June 2026



The slide illustrates the factors contributing to the changes in forecast operating profit for the fiscal year ending June 30, 2026, compared with the operating profit for the fiscal year ended June 30, 2025.

In the Medical Devices and Consumables business, we expect steady growth in consumables due to further market development in the Kansai region, and we also anticipate a certain level of demand for equipment and fixtures. Likewise, the SPD business and Nursing Care Products business are projected to see an increase in profits due to growth in net sales.

Meanwhile, SG&A expenses are expected to increase significantly due to investments in human capital and DX-related systems. Taking these factors into account, consolidated operating profit is expected to be JPY2,000 million, up JPY21 million year on year on.


Consolidated Net Sales: Record-high Forecast

[Consolidated net sales] Record forecast

FY June 2026 Forecast of ¥127.9 billion
(+4.3% YoY)

Sixth consecutive year of sales growth and record highs

(Millions of yen) 160,000



Here are the trends in the semi-annual and full-year results of consolidated net sales for the last 4 years, as well as our forecast for the fiscal year ending June 30, 2026.

Despite the impact of COVID-19 pandemic, inflation, and the weak yen, our business performance has steadily increased each fiscal year, reaching a record high of JPY122,702 million in net sales for the fiscal year ended June 30, 2025.

For the fiscal year ending June 30, 2026, we forecast net sales of JPY127,978 million, a record high and the sixth consecutive year of sales growth.


Consolidated Operating Profit: Forecast of Slight Increase

[Consolidated operating income] Forecast of a slight increase in profits

Forecast for FY6/2026: 2 billion yen
(Up 1.0% year on year)

Aiming to recover to the ¥2 billion level in the fiscal year under review

(Millions of yen)



I will show the trends in the semi-annual and full-year results of consolidated operating profit for the last 4 years and the forecast for the fiscal year ending June 30, 2026. Operating profit for the fiscal year ended June 30, 2025 was JPY1,979 million, marking the first decline in five years.


Operating profit for the fiscal year ending June 30, 2026 is projected to be JPY2.0 billion. Our immediate goal is to recover to the JPY2.0 billion level, after which we aim to achieve sustained growth.

Basic Dividend Policy

Basic policy on dividends

- ① Aiming to increase or maintain dividends
- ② We will endeavor to retain internal reserves for growth investments.

FY6/26 forecast: JPY80



22

This is our basic dividend policy. We aim to increase or maintain dividends, and to endeavor to retain internal reserves in preparation for investment for growth.


The green bar graph in the slide shows the changes in dividend per share. For the fiscal year ended June 30, 2025, we plan to pay a dividend of JPY80 per share, and for the fiscal year ending June 30, 2026, we expect to continue paying a dividend of JPY80 per share.

The blue line graph shows the changes in DOE (dividends on equity). While the average DOE for listed companies in all industrial sectors is said to be in the 2% range, our DOE for the fiscal year ended June 30, 2025 was relatively high at 4.0%.

The orange line graph shows the changes in dividend yield. It was 4.0% for the fiscal year ended June 30, 2025, which was also relatively high.

Cost of Capital and Return on Capital : Current Analysis

Analysis of Capital Cost and Capital Profitability



※Reference value for calculating cost of equity

• Risk-free rate: 10-year JGB yields, β value: about 0.8, market risk premium: about 7%

- Equity spread (%)
(Cost of ROE-equity)
⇒ Approx. 6% to 7%

- For the cost of capital on an ongoing basis
Achieve higher profitability on capital

- Five-year historical mean of ROE
⇒ 14.2%

- **In line with its medium-term management plan**
Continue to invest for growth and development

23

COLBA HEALTHCARE HOLDINGS, Inc.


I will talk about the current status of the cost of capital and return on capital for the Group. We estimate that our cost of equity is around 6%, while our ROE has stayed above 12%, consistently exceeding the cost of capital.

The equity spread, calculated as ROE minus cost of equity, has remained in the range of around 6% to 7%.

We will continue to make investments for growth and development in accordance with our medium-term management plan, while striving to improve profitability.

Initiatives to Improve PBR

Initiatives to Improve PBR



※ Figures in parentheses are as of June 30, 2025 or the previous fiscal year. Figures for the TSE are as of June 2025.

©OLBA HEALTHCARE HOLDINGS, Inc.

24


I will explain about our PBR. As of the end of the previous fiscal year, our PBR was 0.97x. On the other hand, the weighted average PBR for wholesalers in the Standard Market was 1.2x. We aim to exceed the market average PBR in the future.

PBR is broken down into ROE and PER. In order to increase PBR, we recognize that it is particularly important to improve net profit margin and expected growth rate.

For the net profit margin, we will improve productivity by increasing operational efficiency through measures such as digital transformation (DX), and promote the development of new high-value-added businesses. With regard to expected growth rate, we will increase the ratio of overseas business, develop new businesses, and improve our recognition through proactive IR activities. Through these measures, we aim to further increase our PBR.

Vision 2030: Initiatives for Sustainable Growth and Shareholder Returns

VISION2030 Sustainable Growth and Shareholder Returns Initiatives



26

©OLBA HEALTHCARE HOLDINGS, Inc.

This is an overview of our medium-term management plan. As a longer-term management goal, we have set VISION 2030, which is our group goal for 2030.


We are working to achieve the following goals of “becoming Japan’s top trading company for medical equipment,” “generating 20% of operating profit from overseas operations” and “introducing at least 30 new products and services to the market.”

Going forward, we will continue to support the stable provision of medical and nursing care services to medical institutions and patients. We will also expand new businesses such as the sale of automated payment machines for clinics and low-temperature decomposition upcycling units, as well as the growth of our Thai business.

Furthermore, we will strive to enhance corporate value by actively delivering shareholder returns through the utilization of revenues generated from these businesses. The following slide explains the new medium-term management plan that we have developed to achieve our long-term goals.

Medium-Term Management Plan (FY6/2028: Net Sales of JPY142.0 billion and Operating Profit of JPY2.7 billion)

Medium-term management plan (FY June 2028: ¥142 billion in sales, ¥2.7 billion in operating profit)




This is an overview of the medium-term management plan for the period from the fiscal year ending June 30, 2026 to the fiscal year ending June 30, 2028. We will promote OLBA-DX and implement initiatives such as improving productivity and making investments for the future, while fostering a sense of unity and empathy for our business through the sharing of our corporate philosophy, the Employee Charter.

We aim to achieve net sales of JPY142.0 billion and operating profit of JPY2.7 billion on a consolidated basis in the fiscal year ending June 30, 2028, the third year of our medium-term management plan.

Medium-Term Management Plan: Main Points of Initiatives

Medium-Term Management Plan: Key Points of Initiatives

- **OLBA-DX** : Utilization sales quality by streamlining operations and utilizing ICT tools
Working to improve employee IT skills
- **Improve productivity** : Strengthen current operations and innovate logistics (construct new logistics center)
Aiming to realize stable supply and maximize value provided to customers
- **Invest in the future** : Realize development of new businesses and sustainability
Promoting human capital investment and initiatives that take the global environment into account



On subsequent slides

『OLBA-DX』

"Logistics innovation"

"New Business Development"

Explanation focused on "Sustainability"

28

©OLBA HEALTHCARE HOLDINGS, Inc.

I would like to present three main points regarding initiatives set forth in the medium-term management plan.

With OLBA-DX, we aim to improve customer satisfaction by increasing operational efficiency through systems and effective sales activities using ICT tools, while also improving employees' IT literacy and IT skills.

Regarding productivity improvement, we aim to maximize the value provided to customers through measures such as strengthening current operations and innovating logistics, including construction of a new distribution center, to realize a stable supply of medical equipment that is also BCP compliant.

As for investing in the future, we will develop new businesses and work to ensure sustainability, meaning that we will promote human capital investment and global environmental initiatives. In the following slides, we will mainly focus on these three points.

Reforming by OLBA-DX DX Promotion Office

OLBA-DX

Status of DX Measures

- **Promote further sales support and operational efficiency**
 - Expand use of generated AI
 - Expanded use of no-code tools
 - CRM, SFA construction: demonstration stage
 - Renewal of groupware: scheduled for operation in 2026
 - Renovation of sales management system: Scheduled to start operation in 2027

DX Human Resource Cultivation Efforts

- By providing e-Learning with DX literacy training Understanding assessment conducted
- We also encourage employees to take IT passport exams.

[In-house no-code tool utilization study session]



29

©OLBA HEALTHCARE HOLDINGS, Inc.

I will explain our digital transformation (DX) initiatives. In 2021, we established the DX Promotion Office to promote the reform of the operations of each group company.

Initiatives being implemented include expanding the use of generative AI and no-code tools to be used in daily operations. Regarding no-code tools, in addition to internal study sessions, we also have opportunities to present our case studies at external events.

We are also building CRM and SFA systems, which are currently in the pilot stage, and plan to roll them out gradually.

In addition, we are working on projects to upgrade our groupware and sales management systems. We are also enhancing e-Learning and encouraging employees to obtain “IT Passport” to develop DX human resources.

OLBA-DX DX Initiatives

OLBA-DX

Began events for kintone no-code tool

Kintone hive 2025 held in Hiroshima in May 2025

Advocating to the Chugoku-Shikoku Convention and introducing the company's initiatives

With an application created in-house
Achieve greater operational efficiency



Utilizing Cybozu's kintone
no-code tool group-wide

30

©OLBA HEALTHCARE HOLDINGS, Inc.

Our group uses Kintone, a no-code tool provided by Cybozu, Inc. In May 2025, we participated in the Chugoku-Shikoku Conference of “kintone hive 2025,” an event hosted by Cybozu, Inc., where our employees presented our company’s initiatives. Going forward, we will continue to expand the use of no-code tools to improve operational efficiency across all departments.

Logistics innovation

Logistics warehouse construction

● Operation of Li-Flo, an integrated logistics system

Started operation in September 2022 sequentially from the bases of the operating companies' Kawanishi

⇒ Introduction to the entire group is scheduled to be completed



Reinforcement in
inventory control

To reinforce quality
management

Streamlining of
lending business

Effects at Introduction Sites

- Improving the efficiency of product pick and delivery slip output and reducing inventory time through barcode reading and system linkage, etc.

● Shin-Okayama Distribution Center Construction


Decided to construct a new logistics center for the medical equipment business,
scheduled to begin operations in July 2027

Purpose of construction

- Streamlining operations, BCP measures, and building new logistics networks
- Hub base for the supply of medical equipment in the Chugoku-Shikoku region

⇒ Based on the philosophy of "do not stop medical care," we will be responsible for the stable supply of medical devices as a base that supports regional medical care.

※ For details, please refer to "Notice Regarding Lease of Fixed Assets by Lease of Consolidated Subsidiaries"



31

© OLBIA HEALTHCARE HOLDINGS, Inc.

I will explain about our logistics innovation. The integrated logistics system Li-Flo has been gradually put into operation since 2022, and its implementation across the entire group is scheduled to be completed during the current fiscal year.

Li-Flo was developed with the aim of enhancing inventory management, strengthening quality management such as expiration date management, and improving the efficiency of the rental service of orthopedic surgical equipment and other items. This has resulted in more efficient product picking in the warehouse through barcode scanning, more efficient output of delivery slips, and reduced time for inventory counting.

The new Okayama Distribution Center is scheduled to begin operation in July 2027. The purpose of constructing the new center is to improve operational efficiency, enhance business continuity, create a new distribution network, and establish a hub for the supply of medical equipment in the Chugoku and Shikoku regions.

Based on the philosophy of "ensuring continuity of medical care," we aim to support regional medical care and play a role in ensuring the stable supply of medical equipment.

New Business (1) Strong Sales of Thema-SAC

New Businesses ① Strong sales of Thema-SAC®



株式会社 カワニシ バークメド


To foster new businesses

Expansion of
the BarcMed business

Thema-SAC® series of automated settlement machines for clinics

- Installation results for the fiscal year ending June 2025: 255 units
(YoY +29 units)

- Cumulative number of vehicles introduced
: 754 units
(As of the end of June 2025)



Collaboration with retailers
Cashless settlement support



Next, I would like to introduce new businesses. First, I will explain about Thema-SAC, an automated payment machine for medical clinics offered by Kawanishi BarcMed Co., Ltd.

Demand for automated payment machines is increasing, especially among clinics and hospitals that strive to save labor in accounting operations. Thema-SAC is linked to a receipt computer (commonly known as a rececom), a medical fee billing system essential for medical administration. The machine also supports cashless payments.

Over the past year, 255 units were installed, bringing the cumulative number of units installed to 754 as of the end of June 2025. This machine has been sold to clinics and other facilities throughout Japan, with approximately 40% of our sales in the Kanto region. We have sales operations at seven locations nationwide, and so far, we have sales records in 46 prefectures, excluding Yamagata Prefecture.

New Business (2) Establishment of OLSEED, Inc

(January 6, 2025)
New Businesses ② Established OLSEED Co., Ltd.



To foster new businesses
Minimize environmental
impact

Started sales of OLSTECH[®] low-thermal decomposition-type up-cycle unit



OLSTECH| Three characteristics

- 1) Significant reductions in CO₂ and dioxin emissions
- 2) Organic garbage reduced in size to 1/300 volume, secondary use
- 3) Space saving & low running cost (fossil fuel not used)

- Nylon gloves that are disposed of in large quantities in medical and nursing care settings developed from disposing of diapers
- Contribute to reducing environmental impact without transporting and incinerating garbage
- There are inquiries from a variety of fields, not limited to the medical industry.

Recorded sales results in six months after the establishment of the company

Accelerate sales and delivery in the future

33

※ For more information, please refer to "Notice of Establishment of Subsidiaries" and "Notice of Sales of Natural Decomposition Promotion-Type Up-Cycle Unit OLSTECH OrthtechTM"

OLBA HEALTHCARE HOLDINGS, Inc.

In January 2025, we established OLSEED, Inc., a wholly owned subsidiary, and began sales of OLSTECH, a low-temperature decomposition upcycling unit.

OLSTECH utilizes chemical reaction heat to decompose waste without burning it, significantly reducing CO₂ emissions and enabling operation using a standard household outlet. This product was developed through joint research with the Research Center for Environmental Preservation at Osaka University from the idea of wanting to find an environmentally friendly way to dispose of nylon gloves, diapers, and other disposable items that are thrown away every day in large quantities at medical and nursing care facilities.

The unit eliminates the need for transporting and incinerating waste, thereby reducing environmental impact. We have started selling OLSTECH, for the purpose of decomposing general waste, and are currently receiving inquiries from various industries and customers. OLSEED, Inc. has already achieved sales performance within six months of its establishment and will continue to accelerate sales and deliveries.

New Business (3) Babyeets launched

New businesses ③ "Babyeets®" launched

To foster new
businesses

Newborn Live Distribution & Memorial Movie Creation Service "Babyeets®"



Babyeets® | Three Characteristics

- 01 Easy access to read-only cards
- 02 Real-time video viewing from remote areas
- 03 Provision of memorial video after hospitalization

【Thoughts on development】

- With inspiration and newborn records immediately after delivery
Deliver to families and relatives
- To the promotion of attachment to newborns
Aim to contribute



Left: Memorial movie sample
Right: Interview with Director Sugiyama,
Ehime University

Started operation at Ehime University Hospital in December 2024
Delivery to two facilities completed in fiscal 2025.

34

※For more information, see the Newborn Live Distribution & Memorial Movie Creation Service Babyeets Launch Notice.

COLBA HEALTHCARE HOLDINGS, Inc.

The third new business is Babyeets, a service for obstetricians and gynecologists. This service provides live streaming of newborn babies and creates memorial videos.

With Babyeets, family members can watch videos of newborn babies in real time on their smartphones or personal computers anytime, anywhere while the newborn and mother are in the hospital, simply by scanning a dedicated card with a reader. After the newborn is discharged from the hospital, the family can have a memorial video.

Babyeets was developed out of a desire to share the joy of a newborn baby's birth and a record of the newborn with the family and relatives, and to promote the formation of an attachment to the newborn. It was launched at Ehime University Hospital in 2024 and was delivered to two facilities in the fiscal year ended June 30, 2025. Please watch the sample memorial video and the interview with Mr. Sugiyama, Director of Ehime University Hospital, from the QR code on the slide.

Main businesses of THAI OLBA Healthcare

- **Sales of fully automated tablet packaging machines**
Concluded an official sales agent agreement with Takazono Co., Ltd. in Thailand
First delivery to university hospitals completed.
Item 2 is also under delivery preparation.
- **Sales of rehabilitation equipment**
Preparing for sales in cooperation with Morito Co., Ltd. And other Japanese manufacturers
- **Sales of orthopedic implants**
Preparing for sales of domestic medical devices in Thailand

Takazono <https://www.takazono.co.jp/index.html> Co., Ltd.
Morito <https://www.morito.co.jp/> Co., Ltd.

[Commemorative ceremony for the establishment of Bangkok on January 26, 2023]



[Authorized sales agent in Thailand for Takazono Products Co., Ltd.]



35

This is about a new business in the Kingdom of Thailand. In January 2023, we established a joint venture company, THAI OLBA Healthcare Co., Ltd., in the Kingdom of Thailand and launched our overseas business. We currently operate three main businesses.

The first is fully automatic tablet dispensing machines installed in hospital pharmacies and other facilities. We have concluded an authorized distributor agreement with Takazono Corporation in the Kingdom of Thailand and completed delivery to a university hospital in the fiscal year ended June 30, 2025. We are currently preparing for the delivery of the second machine.

The second is the sale of rehabilitation equipment. We are working with MORITOH Co., Ltd. and other Japanese companies to prepare for sales launch.

The third is the sale of orthopedic implants, which are medical devices manufactured in Thailand. We are currently preparing for sales launch.

We intend to expand these efforts to form a business foundation in Thailand, and aim to expand our business with an eye to future expansion into other ASEAN countries.

ESG Initiatives

Sustainability

Environment (environmental)

- Sales of OLSTECH® low-thermal decomposition-type up-cycle unit



↑ low-thermal decomposition-type up-cycle unit "OLSTECH®"

→Carbonate discharged after treatment. Available for building materials and soil improvement materials



Social (Social)



[Human Capital Investment /Health Management]

- Increase in male employees taking childcare leave
- Promotion of female employees activities
- Enhance employee engagement
- Formulation of Health Management Strategy Map
- Long-term revenue support (GLTD) Introduction of the system

[Contribution to local communities]

- Safe and high-quality medical care
- Provision of nursing care equipment and services

Governance (Governance)

- Ensure management transparency, efficiency, and soundness. Enhancement of Group Value
- Promote fair competition and business transactions at all times in our employee charter, and strive to raise the ethical awareness of each and every employee.



↑ Corporate Governance Structure

36

©OLBA HEALTHCARE HOLDINGS, Inc.

I would like to introduce our sustainability-related efforts. First, our ESG initiatives. In the area of Environment, we aim to contribute to the improvement of the global environment through the sale of our low-temperature decomposition upcycling unit, OLSTECH.

As for Social area, we are working on investment in human capital, health & productivity management, and contributions to local communities. I will explain our investment in human capital in the next slide. As a former internal medicine physician, I am actively promoting health & productivity management, and we have been certified as an Outstanding Organization for KENKO Investment for Health for 2025 as well. In addition, in 2024, we introduced the GLTD plan, which compensates employees for a portion of their income in the event that they are unable to work for a long period of time due to illness or injury.

In the area of Governance, we strive to raise the ethical awareness of each employee by embracing the principle of “trying to compete and trade fairly at any time” set out in our Employee Charter, while ensuring the transparency, efficiency, and soundness of corporate management as a company.

Initiatives to Improve Internal Work Environment

Efforts to Improve the Internal Environment

Sustainability

Promotion of diversity

➤ Active participation by women

- 2030 in the Annual Securities Report for the Fiscal Year Ended June 2025

Planning to announce targets for the ratio of women in management positions by the fiscal year ending June

- External to support career development of female employees
Started mentor system

Engagement survey

➤ Improvement of "ease of working" and "job satisfaction"

- Survey started in March 2024

Based on the previous year's improvement, analysis issues and implement improvements

➤ Encouraging men to take childcare leave

- Through maternity leave guidebooks and e-Learning
Developing an environment conducive to enlightenment and acquisition



37

©OLBA HEALTHCARE HOLDINGS, Inc.

As part of our initiatives to improve the internal environment, we support the advancement of women from the perspective of promoting diversity. Specifically, we disclose the percentage of female managers and have introduced an external mentor system aimed at supporting the career development of female employees.

In addition, to encourage male employees to take childcare leave, we are implementing awareness-raising initiatives through the creation of a maternity and childcare leave guidebook and e-Learning, and are working to create an environment that makes it easier to take such leave.

Furthermore, we launched an engagement survey in 2024 with the aim of improving “work environment quality” and “job satisfaction.” We use the year-on-year improvement rate as a benchmark to analyze issues and implement initiatives for further improvement.

Source of Growth: Human Resource Development

Human Resources Development as a Source of Growth


Sustainability

■ Systematic human resource development and acquisition of expertise

OLBA Academy, a 30-year-old internal training system

Building expertise and management capabilities
Gradual expansion of e-Learning courses

We provide opportunities for employees to learn according to their stage of development. Enhance employee engagement



38

©OLBA HEALTHCARE HOLDINGS, Inc.

We would like to share our human resources development initiatives, which is the source of growth for our group. For the purpose of systematic human resource development and expertise acquisition, the Group provide seamless learning opportunities tailored to the stage of individual employees through in-house education system, OLBA Academy, and is also expanding e-Learning courses.

The goal is to gain a deep understanding of medical and nursing care areas, along with product knowledge, in order to propose products and services that contribute to solving customer issues. We will continue to invest in human resources training, which we believe will improve employee engagement and serve as a source of competitive advantage by enhancing the professionalism, skills, and management capabilities of our employees.

Our strengths and utilization and weaknesses and countermeasures

Strengths and Utilization

- **No.1 of shares in Chugoku-Shikoku region (based on trust from customers and suppliers)**
⇒ New investments can be implemented by securing stable profits
- **To invest in human resource development and DX, which are the source of our growth**
⇒ Accurately grasping customer needs through approximately one year of new employee training, etc.
⇒ Supporting sales activities through the utilization of ICT tools

Weaknesses and countermeasures

- **Low profit margin (industry characteristics of wholesalers)**
⇒ High-value-added businesses, such as products developed in-house and overseas expansion, including the Kingdom of Thailand
- **Low share in major metropolitan areas (difficult to enter due to high barriers to entry)**
⇒ Nationwide sales through new businesses. Approximately 40% of the automatic settlement machine Temasac® is sold in the Kanto region.
Sales of OLSTECH® and Babyeets® also commenced this year.

- Electronic catalogue
- Integrated logistics system
- Expenditure adjustment system
- Business card management system
- RPA utilization, etc.

39

©OLBA HEALTHCARE HOLDINGS, Inc.

I will now explain our strengths and how we utilize them, as well as our weaknesses and the measures we are taking to overcome them. First of all, one of our strengths is our number one market share in the Chugoku and Shikoku region. We have gained the trust of our customers and suppliers through our quick response capacity and information provision ability. Based on the trust we have built, we are able to secure stable profits and make new investments.

There are also investments in human resource development and DX, which will be the source of growth. We provide new employees with specialized training to develop their ability to accurately understand customer needs. Through the use of our proprietary electronic catalog system and other ICT tools, we can engage in sales activities that outperform the competition.

Next, I will explain our weaknesses. Our first weakness is the low profit margin. The wholesale business is generally a low-margin business. We aim to improve profitability through overseas expansion, including the Kingdom of Thailand, the sales of high-value-added internally developed products, and enhanced labor productivity.

Our second weakness is the low market share in metropolitan areas. Due to the nature of the industry, it is difficult to expand into new regions. However, approximately 40% of sales of our automated payment machine, Thema-SAC, for clinics are made in the Kanto area, and we plan to increase sales throughout Japan, including metropolitan areas, in the future.

Going forward, we will also focus on the sales of OLSTECH and Babyeets, which can similarly be marketed nationwide.

• Acquisition of new customers and improvement of revenue

- Opening centers in Shikoku and expanding existing centers
- Develop customers in the Chugoku-Shikoku area
- Proposals for hospital management support, such as purchasing price reductions and insurance claim leakage checks

• Wide-area sales of the Medilia inventory management system

- Voluntary investment type at small and medium hospitals
- Simple and accurate inventory management
- Inexpensive billing and remote maintenance

With customer satisfaction
Improve productivity



YouTube video <https://www.youtube.com/watch?v=YxAzGT6Ud>

40

©OLBA HEALTHCARE HOLDINGS, Inc.

This is about our initiatives in the SPD business. In the SPD business, we plan to open a center in the Shikoku area in the medium term and relocate and expand existing centers. We will continue to promote customer development in the Chugoku and Shikoku areas as well as proposals to support hospital management, including reducing purchasing costs and checking for missed insurance claims.

We will also focus on sales of Medilia, a self-administered inventory management system developed in-house for small and medium-sized hospitals. The system facilitates simple and accurate inventory management. Unlike conventional in-hospital and out-of-hospital SPDs, which are operated by our staff, Medilia is operated by hospital staff themselves, making it possible to promote sales over a wide area. You can find an introductory video on YouTube, so please take a look.

• Increase market share in existing areas

- Strengthen customer service by enhancing follow-up system
- Promote sales activities using ICT

• Strengthen services and sell goods

- Strengthen transactions with nursing care facilities
- Hearing aids sales and wheelchair repair services



• In-house construction of residential remodeling for nursing care

- Cultivating new users
- Providing Safety and Security Services



Nursing bed



Wheelchair



Hearing aids



41

COLBA HEALTHCARE HOLDINGS, Inc.

This is about our initiatives in the Nursing Care Products business. In the Nursing Care Products business, we will enhance our customer follow-up system and promote sales activities using digital technology to further increase our market share in existing areas. In addition, we will strengthen sales of goods and provision of services to nursing care facilities, and promote sales of hearing aids and repair services for wheelchairs.

We will also continue to cross-sell products and propose home remodeling to rental customers. We opened sales offices in Onomichi City, Hiroshima Prefecture in 2022 and Kochi Prefecture in April 2025, and will continue to open more new branches in the Setouchi area. In line with the government's policy of the transition from hospital to home care, we expect continued growth in our home nursing care equipment business.

This is the end of the explanation of the financial report. You can find other reference materials in the slide set. Thank you for watching.

Corporate Profile

Trade name Olbas Healthcare Holding Inc

(Former name: Kawanishi Holdings Co., Ltd.)

Head Office 1-3, Shimo-Ishii 1-chome, Kita-ku, Okayama

Founded in May 1921

Established October 1967.

Representative Director and President Yohei Maeshima


Capital 607750000 yen

1393 employees (consolidated, as of the end of June 2025)

Fiscal Year Ended June

Mar. 2020 Listed on the First Section of the TSE
Stock Exchange

2022 Apr. Transitioned to standard market



Diverse business portfolio encompassing orthopedics, cardiovascular, surgical, ophthalmology, and nursing care

43

OLBA HEALTHCARE HOLDINGS, Inc.

History

May, 1921	Established Kawanishi Kikai Kikai Store in Ounji-cho, Okayama City (currently Chuo-cho, Kita-ku, Okayama City).
Sep. 1927	Associated company Kawanishi Machinery Shop reorganized and established.
Jun 1950	Reorganized and established Kawanishi Kikiten Co., Ltd.
1967 Oct	Reorganized and established Kawanishi Medical Equipment Co., Ltd.
1985 Oct	Established Life Care Co., Ltd.
Jul 1996	Established Hosnet Japan Co., Ltd.
1999 Jan.	Merged with three companies, Kagawa Seiki Co., Ltd. and Shikoku Medical Abilities Co., Ltd. At the same time, the company changed its name to Kawanishi Co., Ltd.
2000 Dec	Listed on the Second Section of the Tokyo Stock Exchange.
2004 Jan.	The business division was established as Kawanishi Co., Ltd. through a new split company. At the same time, the company name was changed to KAWANISHI Holdings Co., Ltd.
Jun 2005	Acquired 100% of the shares of Nikko Medical Instruments Co., Ltd.
2012 Jan.	Acquired 100% of the stock of Sansey Medical Machinery Co., Ltd.
2014 Aug.	Head office moved to 1-1-3, Shimo-Ishii, Kita-ku, Okayama, in line with the expansion of the Group's business scope.
2016 Jan.	Established Exora Medical Co., Ltd.
Jul 2019	Established Kawanishibarkmed Co., Ltd.
2020 Mar	Listed on the Second Section of the Tokyo Stock Exchange to the First Section of the Tokyo Stock Exchange.
2021 Jan.	To commemorate its 100th anniversary, the company changed its name to Orba Healthcare Holdings, Inc.
2022 Apr	Transitioned to a standard market in accordance with a review of market categories on the Tokyo Stock Exchange.
Jun 2022	Acquired 100% of the shares of Kawanishibarkmed Co., Ltd.
2023 Jan.	Established Thailand Healthcare Co., Ltd. (THAI OLBA Healthcare Co., Ltd.) in the Kingdom of Thailand.
2025 Jan.	Orsid Co., Ltd. was established.

44

OLBA HEALTHCARE HOLDINGS, Inc.

OLBA Employee Charter

Business Structure

- Contribute to the development of medicine, medical care, and nursing care through business and contribute to the health and longevity of the national
- Promptly and appropriately provide patients and medical providers with the benefits of innovative new features and technologies
- In good faith and continuously to our stakeholders (customers, business partners, employees, local communities, and shareholders)
Providing Value and Pursuing Sustainable Management
- Actively interact inside and outside the industry, foster creativity, and explore frontiers from a global perspective

Organizational Structure

- Respect for human resource development and place emphasis on "management (through human resources)"
- Emphasizing Diversity and Recognizing Diverse Opinions, Values, and Working Styles
- Try to compete and trade fairly at any time
- Results from competition are reinvested to create new value
- Develop an environment where members can be healthy both mentally and physically and have a willingness to contribute

How Members Are

- Have a willingness to grow voluntarily and independently
- Continue to learn modestly without being comfortable with past results
- Not good at free riding to benefit without their own contributions or efforts
- Respect business partners inside and outside the company and engage in business with high ethical standards and pride

45

COLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Balance Sheets (Fiscal 2025)

Millions of yen

Assets	Amount	Change	Liabilities and Net Assets	Amount	Change
Cash and deposits	3,470	738	Trade payables	27,043	843
Trade receivables	26,369	256	Short-term borrowings	400	△199
Commodities	6,417	473	Other	2,378	△538
Other	667	△130	Total current liabilities	29,821	106
Total current assets	36,923	1,337	Long-term debt	1,516	1,516
Tangible fixed assets	5,504	1,144	Other	2,277	129
Intangible fixed assets	625	△21	Total long-term liabilities	3,793	1,645
Investments and other assets	2,817	173	Total liabilities	33,615	1,752
Total fixed assets	8,947	1,296	Total net assets	12,255	881
Total assets	45,871	2,634	Total liabilities and net assets	45,871	2,634

※Change from previous year-end

Net assets per share 2,068.59 yen

46

COLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Statements of Cash Flows (Fiscal 2025)

	Millions of yen	FY June 2024	FY June 2025
Income before income taxes		2,243	1,919
Depreciation and amortization		557	628
Impairment loss		-	26
Decrease (increase) in notes and accounts receivable-trade (increase in Δ)		$\Delta 1,593$	$\Delta 256$
Decrease (increase) in inventories (increase in Δ)		217	$\Delta 399$
Increase (decrease) in notes and accounts payable-trade (decrease in Δ)		827	843
Other		$\Delta 168$	$\Delta 1,135$
Operating cash flow		2,084	1,626
Payment for acquisition of tangible fixed assets		$\Delta 351$	$\Delta 1,445$
Purchases of intangible assets		$\Delta 125$	$\Delta 163$
Loans to subsidiaries and affiliates		$\Delta 160$	-
Other		$\Delta 37$	$\Delta 27$
Investing cash flow		$\Delta 673$	$\Delta 1,635$

47

COLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Statements of Cash Flows (Fiscal 2025)

	Millions of yen	FY June 2024	FY June 2025
Net increase (decrease) in short-term borrowings (Δ)		$\Delta 300$	$\Delta 600$
Proceeds from long-term debt		-	2,000
Repayments of lease obligations		$\Delta 164$	$\Delta 156$
Purchase of treasury stock		$\Delta 221$	$\Delta 135$
Proceeds from sales of treasury stock		1	139
Dividends paid		$\Delta 435$	$\Delta 488$
Other		30	$\Delta 74$
Financial cash flow		$\Delta 1,089$	686
Net increase (decrease) in cash and cash equivalents (decrease in Δ)		321	678
Cash and Cash Equivalents at Beginning of Year		2,359	2,681
Other		-	61
Cash & cash equivalents at year-end		2,681	3,420

48

COLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Financial Data ①

Item	Unit	2021/6	2022/6	2023/6	2024/6	2025/6
Net sales	Millions of yen	102,072	107,959	110,472	118,564	122,702
Operating income	Millions of yen	1,540	2,073	2,151	2,226	1,979
Ordinary income	Millions of yen	1,542	2,119	2,158	2,244	1,962
Profit attributable to owners of parent Net income	Millions of yen	989	1,535	1,414	1,500	1,430
Net assets	Millions of yen	8,131	9,093	10,327	11,373	12,255
Total assets	Millions of yen	36,562	39,968	40,878	43,237	45,871
BPS	Yen	1,336.91	1,513.91	1,712.19	1,922.58	2,068.59
EPS	Yen	162.66	252.80	234.90	251.68	241.43
Equity ratio	%	22.2	22.8	25.3	26.3	26.7
ROE	%	12.8	17.8	14.6	13.8	12.1
ROA	%	4.4	5.5	5.3	5.3	4.4
PER	Times	10.17	6.63	7.70	8.01	8.30
PBR	Times	1.24	1.11	1.06	1.05	0.97

49

COLBA HEALTHCARE HOLDINGS, Inc.

Consolidated Financial Data ②

Item	Unit	2021/6	2022/6	2023/6	2024/6	2025/6
Sales CF	Millions of yen	3,126	2,420	△659	2,084	1,626
Investment CF	Millions of yen	△630	△211	△306	△673	△1,635
Finance CF	Millions of yen	△2,262	△1,169	175	△1,089	686
Cash and cash equivalents	Millions of yen	2,110	3,149	2,359	2,681	3,420
Bank loans	Millions of yen	795	275	955	600	1,916
Number of employees	People	1,261	1,289	1,317	1,354	1,393
Medical equipment	People	913	938	955	982	1,011
Of which, SPD	People	177	175	177	174	179
Nursing care	People	131	135	138	147	153
Of which, headquarters	People	40	41	47	51	50

50

COLBA HEALTHCARE HOLDINGS, Inc.

Summary of FY2025

※New highs for net sales Net sales 122.7 billion yen (+3.5% YoY)	ROE 12.1% (5-year average of 14.2%)	Dividend yield 4.0% (*As of June 30, 2025)
Operating income 1.97 billion yen (△11.1% YoY)	PBR 0.97 times (*As of June 30, 2025)	DOE Dividends on Equity 4.0% (*As of June 30, 2025)

51

COLBA HEALTHCARE HOLDINGS, Inc.

CSR Initiatives Contributing to Social Rooted in Local Communities

Working together with local residents to create a future conducive to regional development and revitalization

Faziano Okayama Club sponsor

Established in 2006 as Okayama Prefecture's first professional soccer club
Decided to be promoted to J1 in 2024



Okayama TEC PLANTER Partner companies

With the creation of new businesses based on technologies originating in Okayama
Venture development and support



Okayama Rivets Team sponsor

Male Table Team established in 2018
Participated in the national T league



Ohara museum of art Official partner



Established in 1930 in Kurashiki City, Okayama Prefecture
Japan's first private art museum focusing on western art

52

COLBA HEALTHCARE HOLDINGS, Inc.

Nippon Medical Manufacturing Commons MINC Association "Study Group on the Latest Trends in Overseas Medical Devices"

On Medical Globe

Sharing and discussing information on the latest overseas medical device information among various industries

Doctors, manufacturers, the Ministry of Economy, Trade and Industry, the Ministry of Health, Labour and Welfare, the Patent Office, AMED・PMDA

Our MG Editorial Department participates and exchanges views (started in October 2017)



53

COLBA HEALTHCARE HOLDINGS, Inc.

Corporate Information/Inquiries

[Fiscal year] From July 1 to June 30 of the following year

[Ordinary General Meeting of Shareholders] Held annually in September

[Stock Exchange Lists] Tokyo Stock Exchange (Standard Market)

Securities code: 2689

[Number of shares per unit] 100 shares

[Contact] OLBA HEALTHCARE HOLDINGS, INC.

Nobuyuji Murata Managing Director, Chief Administrative Officer

info@olba.co.jp

54

COLBA HEALTHCARE HOLDINGS, Inc.

- Although the datum provided in this document is intended to be used with all possible care, the accuracy and completeness of such information is not guaranteed.
- Opinions and forecasts contained in the data are our forecasts based on information available at the time of preparation of the materials, and we do not guarantee any compensation for the results of using such opinions and forecasts. The information in this document is subject to change without notice.
- This material is intended to provide a better understanding of us and is not necessarily intended as a recommendation to invest. We asked investors to make their own decisions on the final outcome of their investments.